[{"id":"a688087c-68be-4853-9780-49620057e35d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04517851","created_at":"2021-01-18T21:38:49.784Z","updated_at":"2025-02-25T15:26:29.899Z","phase":"Phase 2","brief_title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","source_id_and_acronym":"NCT04517851","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • IL1R1 • SLAMF7","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • IL1R1 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2021","start_date":" 02/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-10"},{"id":"5444acae-553a-425f-a15f-fcc1a2b42abb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02826434","created_at":"2021-01-18T13:51:30.016Z","updated_at":"2025-02-25T15:07:08.523Z","phase":"Phase 1","brief_title":"Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer","source_id_and_acronym":"NCT02826434","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-09-23"},{"id":"b1b3d9cc-183d-4233-8eed-c61644ce67f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03362060","created_at":"2021-01-18T16:35:42.711Z","updated_at":"2025-02-25T16:07:16.873Z","phase":"Phase 1","brief_title":"PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03362060","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PVX-410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-09-23"},{"id":"a95cff9a-647e-4c29-8913-c1b9ff377e86","acronym":"RV-MM-PI-0691","url":"https://clinicaltrials.gov/study/NCT01729091","created_at":"2021-01-18T07:34:03.049Z","updated_at":"2024-07-02T16:35:08.785Z","phase":"Phase 2","brief_title":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","source_id_and_acronym":"NCT01729091 - RV-MM-PI-0691","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan • Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/10/2013","start_date":" 06/10/2013","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-04-18"},{"id":"6b7343bd-05b1-474c-8d36-fe39eab91743","acronym":"MM FPBMC","url":"https://clinicaltrials.gov/study/NCT04864522","created_at":"2021-04-29T12:55:37.907Z","updated_at":"2024-07-02T16:35:28.423Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04864522 - MM FPBMC","lead_sponsor":"University of Virginia","biomarkers":" SLAMF7","pipe":"","alterations":" ","tags":["SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SLAMF7 FPBMC"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-11-21"},{"id":"790c7b3c-3603-4602-88a2-0f7f1e2a94af","acronym":"","url":"https://clinicaltrials.gov/study/NCT05028348","created_at":"2023-02-22T17:01:25.614Z","updated_at":"2024-07-02T16:35:54.933Z","phase":"Phase 3","brief_title":"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma","source_id_and_acronym":"NCT05028348","lead_sponsor":"European Myeloma Network","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2023-02-22"},{"id":"167a4ae9-d051-47bd-af76-6495f94636e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634747","created_at":"2021-01-19T20:37:14.629Z","updated_at":"2024-07-02T16:36:11.770Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04634747","lead_sponsor":"OncoPep, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • HLA-A2 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PVX-410"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-04-20"},{"id":"efbe23b4-71d5-4ec8-b170-e888d946d4fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03784378","created_at":"2021-01-18T18:42:53.766Z","updated_at":"2024-07-02T16:36:40.405Z","phase":"Phase 1","brief_title":"Continued Access to RXDX-105","source_id_and_acronym":"NCT03784378","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e agerafenib (RXDX-105)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 12/14/2018","start_date":" 12/14/2018","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2020-10-05"},{"id":"a0d7adfd-bd4d-4476-a063-6c04cc35ce76","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003728","created_at":"2021-01-18T14:46:32.775Z","updated_at":"2025-02-25T14:37:04.983Z","phase":"Phase 2","brief_title":"2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)","source_id_and_acronym":"NCT03003728","lead_sponsor":"University of Arkansas","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Empliciti (elotuzumab) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 07/08/2020","primary_completion_date":" 07/08/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2020-07-10"},{"id":"d66ac5ba-366c-48cf-8572-6aa1136cef2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877811","created_at":"2021-01-17T17:54:36.010Z","updated_at":"2024-07-02T16:37:00.182Z","phase":"Phase 1","brief_title":"Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors","source_id_and_acronym":"NCT01877811","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e agerafenib (RXDX-105)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-04-25"},{"id":"542c8658-9bd5-41f6-8e24-9b1ae4698deb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01441973","created_at":"2021-01-18T05:58:41.442Z","updated_at":"2024-07-02T16:37:14.574Z","phase":"Phase 2","brief_title":"Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma","source_id_and_acronym":"NCT01441973","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" NCAM1","pipe":"","alterations":" ","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 12/28/2011","start_date":" 12/28/2011","primary_txt":" Primary completion: 05/30/2014","primary_completion_date":" 05/30/2014","study_txt":" Completion: 01/17/2017","study_completion_date":" 01/17/2017","last_update_posted":"2018-01-23"}]